SCHEMBL8360756

SCHEMBL8360756

COC(=O)c1ccc(C2C(=O)C(Cc3ccccc3)Cc3cncn32)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CYP19A1 P11511 2/20 0.42
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
ALDH1A1 P00352 2/20 0.40
HSP90AA1 P07900 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
TP53 P04637 2/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
GPX4 P36969 1/20 0.36
GRIN2C Q14957 1/20 0.36
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3574211 0.78 CYP11B1 (0.66) MEN1KMT2ACYP19A1CYP11B1CYP11B2
Hydrochloric Acid SCHEMBL3574374 0.78 CYP11B1 (0.65) MEN1KMT2ACYP19A1CYP11B1CYP11B2
SCHEMBL5769986 0.66 CYP11B1 (0.72) CYP11B1CYP11B2ALDH1A1CYP3A4
SCHEMBL1065113 0.63 HDAC1 (0.61) CYP19A1
SCHEMBL14679534 0.60 NISCH (0.43) MEN1KMT2ASMN1; SMN2ALDH1A1CA1
SCHEMBL6158387 0.60 TSHR (0.67) SMN1; SMN2ALDH1A1MAPTCA1CA2
SCHEMBL1928912 0.60 TSHR (0.67) SMN1; SMN2ALDH1A1MAPTTP53CA1
SCHEMBL31611736 0.60 TSHR (0.60) MEN1KMT2ASMN1; SMN2ALDH1A1HSP90AA1
SCHEMBL13984796 0.60 TSHR (0.60) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
Methyl Benzoate SCHEMBL28249321 0.59 TSHR (0.95) MEN1KMT2ASMN1; SMN2ALDH1A1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004014914-A1 ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS NOVARTIS AG (CH) 2004-02-19 WO disclosed